National Chemotherapy Board (NCB) GOOD PRACTICE GUIDELINE: Promoting Early Identification of Systemic Anti-Cancer Therapies Side Effects: – Two Approaches.
This guidance has been produced by the National Chemotherapy Board in response to concerns that patients often delay reporting serious Systemic Anti-Cancer Therapy (SACT) side effects to dedicated help lines. Two complementary approaches to improve side effect reporting are suggested:
1. Empowerment focuses on equipping patients to take responsibility for identifying and reporting important side effects and may be mediated via technology.
2. Proactive monitoring includes clinician interventions (e.g. telephone support or home visits).
The NCB Good Practice Guidelines are available HERE
Morbidity and mortality within 30 days of Systemic Anti-Cancer Therapy (SACT): Review of Current Practice suggested Standardised Review Process May 2016.
The importance of having mortality meetings to review deaths within 30-days of SACT has been well established. The National Chemotherapy Board (NCB) have recognised that whilst there are many examples of good practice there was inconsistency of approach between centres which may limit sharing of learning. The NCB have summarised the key details of the processes currently being used and have developed a proposed template for an operational policy and proforma.
Please click HERE for the covering letter and click HERE for the accompanying document
Click hereto read the UKONS paper on 'Best practice in nurse-led chemotherapy review: a position statement' at ecancer.org, or download the pdf
Click here to access more information about the award-winning 24 hour triage rapid assessment and access toolkit and how to order copies.